tbuckley/cabot-search huggingface dataset:
EPIDEMIOLOGICAL STUDIES ON RESPIRATORY INFECTIONS OF THE RABBIT
Authors: Leslie T. Webster
Journal: The Journal of Experimental Medicine (1926)

In several copies of the April number of The Journal oF Experi mental Medicine (Vol. xliii, No. 4), through an error in binding, Plates 20–23 were inserted after page 588 instead of after page 572. We shall be glad to bind your copy correctly if you will return it to The Williams &amp; Wilkins Company, Mount Royal and Guilford Avenues, Baltimore, Maryland.
Association of FIB-4 score with major cardiovascular events (MACE) in real-world populations diagnosed with NASH or NAFLD in US clinical practice
Authors: Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, Nezam Afdhal
Journal: Journal of Hepatology (2020)
Should heroin be available for pain?
Authors: W. C. Farr
Journal: JAMA (1979)

<h3>To the Editor.—</h3> I could not agree more with most of the recent COMMENTARY by John R. Lewis, PhD, "Should Heroin Be Available To Treat Severe Pain?" (240:1601, 1978). However, I believe he missed the point with respect to one specific advantage of heroin over morphine in the treatment of severe pain in patients with terminal cancer. Saunders<sup>1</sup>and Twycross<sup>2</sup>at St Christopher's Hospice in London have consistently shown that there is a distinct advantage to the use of heroin over morphine in a small, select group of patients. They are those patients who require large doses of injectable narcotics. Heroin's use is more advantageous than morphine's in that it is extremely soluble and therefore permits using a smaller injected volume (heroin, 100 mg/0.2 mL, vs morphine, 15 mg/1.0 mL). Heroin is not a more effective analgesic. In my experience with the treatment of more than 280 terminally
Abstract 15951: Psychosocial Wellbeing Does Not Affect Muscle Pain and Quality of Life During Atorvastatin Treatment
Authors: Amanda L Zaleski, Beth A Taylor, Linda S Pescatello, Gregory A Panza, Jeffrey A Capizzi, Adam Grimaldi, Charles M White, Paul D Thompson
Journal: Circulation (2015)

Introduction: HMG-CoA reductase inhibitors (statins) are generally well-tolerated, although muscle weakness and pain have been reported in ~10% of statin users. However, many self-reported muscle side effects are non-specific. As mental health influences self-perception of pain, we sought to assess the effect of baseline well-being and depression on self-reported muscle pain and quality of life (QOL) after 6 months of atorvastatin (ATORVA) 80 mg/d or placebo in healthy, statin-naïve adults. Hypothesis: We hypothesized that lower levels of well-being and higher levels of depression would result in higher self-reported pain that interferes with QOL after statin therapy. Methods: The Psychological General Well-Being Index (Well-Being; n=82) and Beck Depression Inventory (Depression; n=55) were administered at baseline in subjects (aged 59.5+1.2 yrs) from STOMP (Effect of Statins on Skeletal Muscle Performance; Clinical Trials #NCT00609063). Muscle pain (Short-Form McGill Pain Questionnaire [SF-MPG]) and pain that interferes with QOL (Brief Pain Inventory [BPI]), were also measured before and after drug treatment. Results: At baseline, there were no group differences in Well-Being, Depression, or pain measures between groups (ps ≥0.05). Baseline Well-Being correlated with baseline BPI pain severity (r=-0.309, p&lt;0.01) and BPI pain interference with QOL (r=-0.271, p&lt;0.05); including both affective and activity subcomponents (ps&lt;0.05). Baseline Depression correlated with baseline pain (r=0.313, p&lt;0.05). Pain severity and interference with QOL scores were not different between statin users and controls after 6 mo of ATORVA (ps≥0.05). Baseline Well-Being and Depression were not significant predictors of pain after 6 mo of ATORVA (ps≥0.05 for overall effects and interactions). Conclusions: Lower levels of psychosocial well-being and higher levels of depression are associated with greater non-specific muscle pain, however, they are not associated with statin-associated muscle side effects or QOL after 6 mo of ATORVA in otherwise healthy adults. Trial Registration: NCT00609063
Therapy for septic arthritis
Authors: G. Ho
Journal: JAMA (1982)

The usefulness of the results of serial cultures of synovial fluid in assessing the response to medical therapy of acute bacterial joint infections was examined. A five-year retrospective survey disclosed 32 synovial fluid culture-proved cases of septic arthritis in adults. Thirteen of the patients had well-documented evidence of (1) duration of articular symptoms (presumably reflecting the presence of infection) and (2) subsequent time required to sterilize the synovial fluids (as determined by serial synovial fluid cultures). We found a positive correlation between duration of symptoms and length of time during which serial cultures of synovial fluids remained positive after initiation of treatment. In the seven patients with good outcome, cultures remained positive for 2.4±1.9 days, as opposed to 8.2±2.4 days in the six patients with poor results. The time required to sterilize the synovial fluid appears to be a reliable indicator of response to therapy and an accurate predictor of outcome. Our data show that the rapidity in achieving synovial fluid sterility is of paramount importance in the successful treatment of infection, preservation of articular integrity, and restoration of joint function. (<i>JAMA</i>1982;247:797-800)
Observations on the Treatment of Asthma
Authors: T L Pridham
Journal: BMJ (1860)

the brain; while the nature of the attack itself (so distinctly excito-niotor), anld the defective tone of the lower limbs, point alilke to the spinial cord.It also adds another to the many testimoniies wve have to the power that cod-liver oil exercises over the assimilative functions generally.OBSERVATIONS ON THE TREATMENT OF ASTHMA.
STARCH DIGESTION IN EARLY LIFE
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Perioperative Supraventricular Tachyarrhythmia
Authors: Thomas H. Lee
Journal: Annals of Internal Medicine (1999)

Letters18 May 1999Perioperative Supraventricular TachyarrhythmiaDavid Amar, MDDavid Amar, MDMemorial Sloan-Kettering Cancer Center; New York, NY 10021 (Amar)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-130-10-199905180-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I read with interest Polanczyk and colleagues' article (1) on perioperative supraventricular tachyarrhythmia, especially after cardiothoracic operations. Although the authors demonstrate that age 70 years or older is an independent preoperative correlate of arrhythmia after surgery, it would have been helpful not to dichotomize this important risk factor but to report and compare the actual age between patients who did and those who did not develop arrhythmias. The authors confirm that atrial fibrillation is the most common supraventricular arrhythmia in the perioperative period. As in atrial fibrillation unrelated to surgery, age older than 60 years is consistently ...References1. Polanczyk CA, Goldman L, Marcantonio ER, Orav EJ, Lee TH. Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med. 1998;129:279-85. LinkGoogle Scholar2. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med. 1997;336:1429-34. CrossrefMedlineGoogle Scholar3. Amar D, Roistacher N, Burt ME, Rusch VW, Bains MS, Leung DH, et al . Effects of diltiazem versus digoxin on dysrhythmias and cardiac function after pneumonectomy. Ann Thorac Surg. 1997;63:1374-82. CrossrefMedlineGoogle Scholar4. Ritchie AJ, Bowe P, Gibbons JR. Prophylactic digitalization for thoracotomy: a reassessment. Ann Thorac Surg. 1990;50:86-8. CrossrefMedlineGoogle Scholar5. Falk RH, Leavitt JJ. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med. 1991;114:573-5. LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Memorial Sloan-Kettering Cancer Center; New York, NY 10021 (Amar) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSupraventricular Arrhythmia in Patients Having Noncardiac Surgery: Clinical Correlates and Effect on Length of Stay Carisi A. Polanczyk , Lee Goldman , Edward R. Marcantonio , E. John Orav , and Thomas H. Lee Perioperative Supraventricular Tachyarrhythmia Thomas H. Lee and Carisi A. Polanczyk Metrics 18 May 1999Volume 130, Issue 10Page: 863-864KeywordsArrhythmiaAtrial fibrillationCardiothoracic surgeryDiureticsMedical risk factorsRandomized trialsRisk managementSurgeryTachycardiaThoracic surgery Issue Published: 18 May 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Précis of<i>The Myth of Martyrdom: What Really Drives Suicide Bombers, Rampage Shooters, and Other Self-Destructive Killers</i>
Authors: Adam Lankford
Journal: Behavioral and Brain Sciences (2014)

Abstract For years, scholars have claimed that suicide terrorists are not suicidal, but rather psychologically normal individuals inspired to sacrifice their lives for an ideological cause, due to a range of social and situational factors. I agree that suicide terrorists are shaped by their contexts, as we all are. However, I argue that these scholars went too far. In The Myth of Martyrdom: What Really Drives Suicide Bombers, Rampage Shooters, and Other Self-Destructive Killers , I take the opposing view, based on my in-depth analyses of suicide attackers from Asia, Africa, Europe, the Middle East, and North America; attackers who were male, female, young, old, Islamic, and Christian; attackers who carried out the most deadly and the least deadly strikes. I present evidence that in terms of their behavior and psychology, suicide terrorists are much like others who commit conventional suicides, murder-suicides, or unconventional suicides where mental health problems, personal crises, coercion, fear of an approaching enemy, or hidden self-destructive urges play a major role. I also identify critical differences between suicide terrorists and those who have genuinely sacrificed their lives for a greater good. By better understanding suicide terrorists, experts in the behavioral and brain sciences may be able to pioneer exciting new breakthroughs in security countermeasures and suicide prevention. And even more ambitiously, by examining these profound extremes of the human condition, perhaps we can more accurately grasp the power of the human survival instinct among those who are actually psychologically healthy.
Discussion by Rosenow.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Demyelinating Diseases
Authors: George A. Schumacher
Journal: New England Journal of Medicine (1960)

THE demyelinating diseases of the nervous system remain a challenge to scientific investigation and a stumbling block in medical therapy. Comprising an important group of neurologic disorders, they constitute one of the major unsolved problems of medicine. The tragic toll of crippling disability, mental deterioration and death resulting from these conditions has been associated with the disturbing fact that demyelination as a pathologic process, though exceedingly frequent in nervous tissues, with occurrence also in numerous disorders not classified under the primary demyelinating diseases, remains of unexplained mechanism. Clinical investigators and basic scientists have been puzzled and fascinated by this phenomenon . . .
Hypercoagulable States
Authors: Wendell A. Wilson
Journal: Annals of Internal Medicine (1997)

Letters15 December 1997Hypercoagulable StatesWendell A. Wilson, MD and Azzudin E. Gharavi, MDWendell A. Wilson, MDLouisiana State University Medical Center; New Orleans, LA 70112-2822Search for more papers by this author and Azzudin E. Gharavi, MDLouisiana State University Medical Center; New Orleans, LA 70112-2822Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-12-199712150-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest the review by Thomas and Roberts [1], which mainly discussed genetic defects in coagulation that cause hypercoagulability and thrombosis. We question the authors' summary statement: “No evidence indicates that the measurement of endogenous anticoagulant pathways has a useful role to play in assessing patients at risk for arterial thrombosis.” This generalization is probably relevant to arteriosclerotic thrombosis, but it does not apply to arterial thrombosis in patients suspected of having the antiphospholipid syndrome. As correctly stated by the authors themselves earlier in their review, “… persons with hypercoagulable states include patients with the ...References1. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med. 1997; 126:638-44. Google Scholar2. Brandt JJ, Triplett DA, Alving B, Scharrer I. Scientific and Standardization Committee Communications: Criteria for the diagnosis of lupus anticoagulants-an update. Thrombosis Haemost. 1995; 74:1185-90. Google Scholar3. Harris EN. The Second International Anticardiolipin Workshop/The Kingston Antiphospholipid Study (KAPS). Am J Clin Pathol. 1990; 94:476-84. Google Scholar4. Khamashta MA, Cuadrado MJ, Mujic F, Traub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med. 1995; 332:993-7. Google Scholar5. Wilson WA, Gharavi AE. Hughes syndrome: perspectives on thrombosis and antiphospholipid antibody. Am J Med. 1997; 101:574-5. Google Scholar Author, Article, and Disclosure InformationAffiliations: Louisiana State University Medical Center; New Orleans, LA 70112-2822 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySecondary Prevention after Ischemic Strokes due to Hypercoagulable StatesHemostatic Disorders Presenting as Cerebral Infarction 15 December 1997Volume 127, Issue 12Page: 1128KeywordsAntiphospholipid syndromeGeneticsInternational normalized ratioLupus erythematosusPartial thromboplastin timeProtein C deficiencyProtein S deficiencyProthrombin timeThrombosisVenoms Issue Published: 15 December 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Highlights
Authors: Magnus Coauthors, D Kimberlin, Adam Zolotor
Journal: JAMA Pediatrics (2015)

Given the number of individuals in the United States with limited English profi ciency (LEP), there is a need to develop and test eff ective and timely methods of providing interpretation in health care settings.Lion and colleagues conduct a randomized trial of traditional telephone vs video interpreter use in 290 Spanish-speaking LEP parents of children treated in the emergency department.Families with LEP who received video interpretation were more likely to correctly name the child's diagnosis and had fewer lapses in interpreter use.The accompanying editorial by Jacobs and Vela discusses the implications for providing appropriate care for LEP patients.
Juvenile Temporal Arteritis
Authors: J. T. Lie
Journal: JAMA (1975)

Two young adults (aged 21 and 22 years) and two children (aged 7 and 8 years) complained of an unsightly, soft, painless unilateral nodule in the temporal region, ranging from 0.5 to 1.5 cm in diameter, clinically diagnosed as lipoma, sebaceous cyst, or dermoid cyst. In each instance, the patient had no evidence of systemic disease or history of trauma, and the nodule was excised for cosmetic reasons. Histologic examination of the lesions showed non-giant-cell granulomatous inflammation of the temporal arteries with intimal proliferation and microaneurysmal disruption of the media. Whether the lesions represent a juvenile form of temporal arteritis, an unusual form of localized polyarteritis nodosa, or Kimura disease (subcutaneous angiolymphoid hyperplasia with eosinophilia) remains conjectural. (<i>JAMA</i>234:496-499, 1975)
Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center.
Authors: Vinayak Muralidhar, Meredith M. Regan, Lillian Werner, Mari Nakabayashi, Carolyn Evan, Joaquim Bellmunt, Toni K. Choueiri, Aymen Elfiky, Lauren Christine Harshman, Rana R. McKay, Mark Pomerantz, Christopher Sweeney, Mary-Ellen Taplin, Philip W. Kantoff, Paul L. Nguyen
Journal: Journal of Clinical Oncology (2016)

33 Background: We wished to evaluate the incidence and predictors of the use of long-term (2-3 years) vs. shorter-term androgen deprivation therapy (ADT) in radiation-treated men with high-risk prostate cancer. Methods: We identified 302 patients from the Dana-Farber Cancer Institute patient registry diagnosed with high-risk prostate cancer (T3a or PSA &gt; 20 ng/mL or Gleason score 8-10) between 1993 and 2015. We assessed the intended duration of ADT and used multivariable Cox regression to evaluate predictors of receiving shorter-course ADT than recommended by guidelines (&lt; 2 years). Results: The course of ADT intended by physicians increased following the 2009 publication of trials showing the superiority of 2-3 years versus 4-6 months of ADT, with 43.5% intending ≥ 2 years before vs. 61.4% after (p=0.014). Starting in 2010, 49.4% of patients actually received less than 2 years of ADT. The most common reasons for receipt of shorter-course ADT were intolerance of ADT side effects, patient comorbidity/age, the presence of T3a on MRI only as the sole high-risk feature, or participation in a clinical trial. ACE-27 moderate to severe comorbidity (adjusted hazard ratio [AHR]=2.94), Gleason score less than 8 (AHR=5.66), and PSA &lt; 20 ng/mL (AHR=4.19) all predicted receipt of shorter-course ADT (p&lt;0.05 in all cases). Conclusions: In a tertiary-care setting, rates of long-course ADT for high-risk disease have increased since the 2008/2009 trials supporting its use. However, approximately half of patients continued to receive shorter-course ADT, often due to intolerance of side effects, underlying comorbidity, or physician judgment about the aggressiveness of the disease.
Minerva
Journal: BMJ (1998)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Minerva Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia*1
Authors: A LANGNAS
Journal: Hepatology (1995)

We recently observed that more than one third of pediatric patients who presented with non-A, non-B fulminant liver failure (FLF) also developed aplastic anemia (AA) either before or shortly after liver transplantation. Factors involved in the suppression of bone marrow could be the same as those causing hepatic failure. We considered parvovirus B19 a candidate etiologic agent because of the known tropism of B19 for erythroid precursors. Archived liver and serum from six patients undergoing liver transplantation for non-A, non-B, non-C FLF with associated AA were analyzed for the presence of B19 DNA and anti-B19 serology. An age- and gender-matched control group (N = 44) was analyzed in parallel. B19 DNA studies and anti-B19 serology were performed in a blinded fashion. B19 serologies were performed by antibody capture enzyme-linked immunosorbent assay (ELISA). B19 DNA was detected after polymerase chain reaction (PCR) amplification of target B19 DNA sequences in liver and serum. Liver tissue showed evidence of B19 DNA in four of six (66%) patients with FLF and associated AA. Two of 4 patients with cryptogenic FLF but without AA had B19 DNA detected in the liver tissue. Of the 34 remaining controls, only 5 (15%) showed evidence of B19 DNA in liver tissue (66% vs. 15%, P = .016). B19 DNA was not detected in any of the test or control sera. This study provides evidence to support the role of parvovirus B19 in the development of FLF and associated AA.
COUNTER TRACTION USING CLIPS AND RUBBER BANDING FOR ENDOSCOPIC SUBMUCOSAL DISSECTION OF A LATERALLY SPREADING TUMOR INVOLVING A DIVERTICULUM IN THE COLON
Authors: J Albouys, R Legros, A Charissoux, M Dahan, D Sautereau, M Pioche, J Jacques
Journal: Endoscopy (2019)

In addition to the possibility of en bloc resection without size limitations, endoscopic submucosal dissection (ESD) is also a novel option for endoscopic treatment of lesions involving a diverticulum in the colon or appendix. Generally, when employing EMR, these types of lesions have a high risk of perforation or incomplete resection.
Reversible renal artery stenosis associated with pheochromocytoma
Authors: D. C. Brewster
Journal: JAMA (1982)

An extra-adrenal pheochromocytoma was associated with ipsilateral renal artery stenosis. The pheochromocytoma was initially overlooked when renovascular hypertension was mistakenly diagnosed. The renal artery stenosis proved to be functional and was totally reversed by adrenergic blocking agents, given for hypertension, and subsequent tumor removal. Functional renal artery stenosis caused by catecholamine-induced vasospasm may be more common than previously recognized with pheochromocytomas, particularly those in an extra-adrenal location in the renal hilum. (<i>JAMA</i>1982;248:1094-1096)